139

I

m

j

2499US0P

SMITTAL LETTER TO THE UNITED STATES GNATED/ELECTED OFFICE (DO/EO/US)

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

NCERNING A FILING UNDER 35 U.S.C. 371

INTERNATIONAL FILING DATE

TERNAS ONAL APPLICATION NO 98/05709

F OF INVENTION

December 17, 1998

PRIORITY DATE CLAIMED December 19, 1997

Phosphonocephem Derivatives, Their Production and Use APPLICANT(S) FOR DO/EO/US Tomovasu ISHIKAWA et al. Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5 X A copy of the International Application as filed (35 U.S.C. 371(c)(2)) is transmitted herewith (required only if not transmitted by the International Bureau). has been transmitted by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US). A translation of the International Application into English (35 U.S.C. 371(c)(2)). * Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) are transmitted herewith (required only if not transmitted by the International Bureau). have been transmitted by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11, to 16, below concern document(s) or information included: An Information Disclosure Statement under 37 CFR 1.97 and 1.98. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.



A FIRST preliminary amendment.

A substitute specification.

Other items or information:

A SECOND or SUBSEQUENT preliminary amendment.

A change of power of attorney and/or address letter.

Express mail label #: EJ918102795US

* This includes the Request and Specification 48 total pages, including Claims 1-28 and Abstract.

422 Rec'd PCT/PTO 0 6 JUN 2000

ľ	S. APPLO 9 N 7 15	NATIONAL APPLICATION NO. PCT/JP98/05709			ATTORNEYS DOCKET NUMBER 2499USOP		
h	17. X The foll	landa Carana da distributa			CALCULATIONS	PTO USE ONLY	
	BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO					·	
	but all claims did not satisfy provisions of PCT Article 33(1)-(4)						
L	ENTER APPROPRIATE BASIC FEE AMOUNT =				\$ 840.00		
	Surcharge of \$130.00 for furnishing the oath or declaration later than \ 20 \ 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				s		
L	CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE			
. 1	Total claims	28 - 20 =	8	X \$18.00	\$ 144.00		
ŀ	ndependent claims		4	X \$78.00	\$ 312.00		
1	MULTIPLE DEP	ENDENT CLAIM(S) (if appli		+ \$260.00	\$ 0.00		
٠.	•	TOTAL	OF ABOVE CALCULAT	TIONS =	§ 1,296.00		
Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement must also by filed (Note 37 CFR 1.9, 1.27, 1.28).							
19			\$ 1,296.00				
)	SUBTOTAL = \$ 1,296.00 Processing fee of \$130.00 for furnishing the English translation later than 20 30 \$ months from the earliest claimed priority date (37 CFR 1.492(f)).						
TOTAL NATIONAL FEE = \$ 1,296.00 Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property + \$ 40.00							
)		TOTAL FEES ENCLOSED =					
3					Amount to be refunded:	s	
1					charged:	S	
	a.						
	NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status. SEND ALL CORRESPONDENCE TO. CUSTOMER NO. 23,115 Miriam Sohn (Reg. No. 35,368) Takeda Pharmaceuticals America, Inc. Patent Office 1745 Jefferson Davis Highway, Suite 408, Arlington VA 22202, USA Phone: (703) 416-5160 Fax: (703) 416-5163 REGISTRATION NUMBER REGISTRATION NUMBER						
1		l: dmsohn@aol.com		Da	te: June 2, 2000		